SynthesisScientific reports2021

Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials.

Szabolcs Kiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.